<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>142</number>
    <updateDate>2025-07-21T19:32:26Z</updateDate>
    <updateDateIncludingText>2025-07-21T19:32:26Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2023-01-30</introducedDate>
    <congress>118</congress>
    <committees>
      <item>
        <systemCode>ssju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported By</name>
            <date>2023-03-01T21:18:59Z</date>
          </item>
          <item>
            <name>Markup By</name>
            <date>2023-02-09T17:53:19Z</date>
          </item>
          <item>
            <name>Referred To</name>
            <date>2023-01-30T23:14:26Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2023-03-01</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2023-03-01</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-03-01</actionDate>
        <text>Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-02-09</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-01-30</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on the Judiciary.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2023-01-30</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>K000367</bioguideId>
        <fullName>Sen. Klobuchar, Amy [D-MN]</fullName>
        <firstName>Amy</firstName>
        <lastName>Klobuchar</lastName>
        <party>D</party>
        <state>MN</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>G000386</bioguideId>
        <fullName>Sen. Grassley, Chuck [R-IA]</fullName>
        <firstName>Chuck</firstName>
        <lastName>Grassley</lastName>
        <party>R</party>
        <state>IA</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000563</bioguideId>
        <fullName>Sen. Durbin, Richard J. [D-IL]</fullName>
        <firstName>Richard</firstName>
        <lastName>Durbin</lastName>
        <party>D</party>
        <state>IL</state>
        <middleName>J.</middleName>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001096</bioguideId>
        <fullName>Sen. Cramer, Kevin [R-ND]</fullName>
        <firstName>Kevin</firstName>
        <lastName>Cramer</lastName>
        <party>R</party>
        <state>ND</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001277</bioguideId>
        <fullName>Sen. Blumenthal, Richard [D-CT]</fullName>
        <firstName>Richard</firstName>
        <lastName>Blumenthal</lastName>
        <party>D</party>
        <state>CT</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>K000377</bioguideId>
        <fullName>Sen. Kelly, Mark [D-AZ]</fullName>
        <firstName>Mark</firstName>
        <lastName>Kelly</lastName>
        <party>D</party>
        <state>AZ</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>V000128</bioguideId>
        <fullName>Sen. Van Hollen, Chris [D-MD]</fullName>
        <firstName>Chris</firstName>
        <lastName>Van Hollen</lastName>
        <party>D</party>
        <state>MD</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001288</bioguideId>
        <fullName>Sen. Booker, Cory A. [D-NJ]</fullName>
        <firstName>Cory</firstName>
        <lastName>Booker</lastName>
        <party>D</party>
        <state>NJ</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>O000174</bioguideId>
        <fullName>Sen. Ossoff, Jon [D-GA]</fullName>
        <firstName>Jon</firstName>
        <lastName>Ossoff</lastName>
        <party>D</party>
        <state>GA</state>
        <sponsorshipDate>2023-02-01</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>E000295</bioguideId>
        <fullName>Sen. Ernst, Joni [R-IA]</fullName>
        <firstName>Joni</firstName>
        <lastName>Ernst</lastName>
        <party>R</party>
        <state>IA</state>
        <sponsorshipDate>2023-02-01</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>W000800</bioguideId>
        <fullName>Sen. Welch, Peter [D-VT]</fullName>
        <firstName>Peter</firstName>
        <lastName>Welch</lastName>
        <party>D</party>
        <state>VT</state>
        <sponsorshipDate>2023-02-09</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2024-03-13T15:24:00Z</pubDate>
        <title>S. 142, Preserve Access to Affordable Generics and Biosimilars Act</title>
        <url>https://www.cbo.gov/publication/60083</url>
        <description>As reported by the Senate Committee on the Judiciary on March 1, 2023</description>
      </item>
    </cboCostEstimates>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Civil actions and liability</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Competition and antitrust</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Contracts and agency</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Federal Trade Commission (FTC)</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Intellectual property</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Judicial review and appeals</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Licensing and registrations</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Manufacturing</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Marketing and advertising</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2023-03-01T19:30:26Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2023-02-14T16:15:31Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-01-30</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2023-06-01T15:48:46Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;b&gt;Preserve Access to Affordable Generics and Biosimilars Act&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.&lt;/p&gt; &lt;p&gt;An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.&lt;/p&gt; &lt;p&gt; When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.&lt;/p&gt; &lt;p&gt;The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.&lt;/p&gt;</text>
        </cdata>
      </summary>
      <summary>
        <versionCode>25</versionCode>
        <actionDate>2023-03-01</actionDate>
        <actionDesc>Reported to Senate</actionDesc>
        <updateDate>2023-07-18T15:34:11Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;b&gt;Preserve Access to Affordable Generics and Biosimilars Act&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.&lt;/p&gt; &lt;p&gt;An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.&lt;/p&gt; &lt;p&gt; When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.&lt;/p&gt; &lt;p&gt;The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <updateDate>2024-07-24T15:23:46Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <updateDate>2024-05-24T13:42:49Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <titleTypeCode>103</titleTypeCode>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <updateDate>2024-05-24T13:42:28Z</updateDate>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.</title>
        <updateDate>2023-02-10T03:28:48Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2023-03-01T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s142rs/xml/BILLS-118s142rs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2023-01-30T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s142is/xml/BILLS-118s142is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-03-01</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
